Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Citibank´s $3.000-Gold-Prognose und die $60-Millionen-Wette, die den Mining-Sektor neu definieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 461279 | ISIN: BMG2097Z1471 | Ticker-Symbol: N/A
1-Jahres-Chart
CHEVALIER INTERNATIONAL HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CHEVALIER INTERNATIONAL HOLDINGS LTD 5-Tage-Chart
PR Newswire
193 Leser
Artikel bewerten:
(1)

Ethypharm announces the appointment of Éric CHEVALIER as Group Human Resources Director

SAINT-CLOUD, France, Oct. 4, 2024 /PRNewswire/ -- Denis DELVAL, President & CEO of the Ethypharm Group, announces the appointment of Éric CHEVALIER as Group Human Resources Director with effect from 1 October 2024.

Eric CHEVALIER - Group Human Resources Director of Ethypharm

With 20 years' experience in the Human Resources function, including 10 years in the pharmaceutical industry, Éric Chevalier brings a wealth of experience from a variety of sectors, giving him a global and operational vision of HR issues.

Throughout his career, Éric Chevalier has held key positions in leading companies. In particular, he was Director of Human Resources at Biogen for 4 years, after having been HR Manager for several industrial organisations at General Electric Healthcare. He began his career at Coca-Cola Entreprises, where he spent nine years as an HR generalist. 20 years of experience have enabled him to acquire a comprehensive and integrated vision of HR, as well as solid expertise in the various key areas of Human Resources.

More recently, as Director of Human Resources at AstraZeneca France, Éric Chevalier oversaw all HR activities in France against a backdrop of strong growth. He helped set up high-performance organisations while promoting an open and committed working environment, focused on developing the skills of all employees.

Éric CHEVALIER holds a Master 2 in Human Resources Management from CIFFOP - Université Panthéon Assas - Paris II, as well as a Master in Economics from Paris I Panthéon-Sorbonne.

Denis DELVAL, President & CEO of the Ethypharm Group, said: "The recruitment of this key position for the development and evolution of Ethypharm led me to call on an experienced professional. We are convinced that Eric, with his experience and people-centred approach, will be able to support our Group's growth while reinforcing a positive and committed corporate culture".

Eric CHEVALIER, newly appointed Director of Human Resources, added: "I am delighted to be joining Ethypharm and enthusiastic about helping to strengthen its position as a key international player in the pharmaceutical industry. I look forward to working with the teams to develop talent and foster a humane and collaborative working environment"

About Ethypharm

Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential medicines, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine.

Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.

Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations.

Our six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.

Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them.

To find out more about Ethypharm, visit http://www.ethypharm.com and follow us on Linkedin.

Media Contact: Avril PONNELLE - presse@ethypharm.com

Photo - https://mma.prnewswire.com/media/2523477/Eric_Chevalier_Ethypharm.jpg
Logo - https://mma.prnewswire.com/media/1917067/3701425/Ethypharm_Logo.jpg

Ethypharm Logo (PRNewsfoto/Ethypharm)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ethypharm-announces-the-appointment-of-eric-chevalier-as-group-human-resources-director-302267731.html

© 2024 PR Newswire
Sondersituation: Vervielfachungschance bei diesen Goldaktien

Der Goldpreis haussiert und schwingt sich von Hoch zu Hoch. Getrieben von geopolitischen Unsicherheiten sowie der Aussicht auf eine lockere Geldpolitik der FED gehen Experten aktuell von weiter steigenden Notierungen bis sogar in den Bereich von 3.000 US-Dollar je Unze Gold aus.

Im Schatten des Basispreises notieren Goldproduzenten aus der zweiten Reihe sowie Explorationsunternehmen noch weit weg von ihren historischen Höchstständen entfernt und bieten dadurch erhebliches Aufholpotential.

In diesem kostenlosen Report geben wir Ihnen Favoriten an die Hand, die aufgrund von Sondersituation die Chance auf eine Kursvervielfachung besitzen.

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von dem weiter steigenden Kurs des Edelmetalls.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.